Suppr超能文献

神经外科医生作为局部肿瘤学家:恶性胶质瘤治疗中的细胞与分子神经外科手术

The neurosurgeon as local oncologist: cellular and molecular neurosurgery in malignant glioma therapy.

作者信息

Dunn Ian F, Black Peter McL

机构信息

Brain Tumor Laboratories and Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA.

出版信息

Neurosurgery. 2003 Jun;52(6):1411-22; discussion 1422-4. doi: 10.1227/01.neu.0000064808.27512.cf.

Abstract

Malignant gliomas are among the most challenging of all cancers to treat successfully, being characterized not only by aggressive proliferation and expansion but also by inexorable tumor invasion into distant brain tissue. Although considerable progress has been made in the treatment of these tumors with combinations of surgery, radiotherapy, and chemotherapy, these efforts have not been curative. Neurosurgeons as oncologists have increasingly turned their attention to therapies on a molecular scale. Of particular interest to neurosurgeons is the ability to deliver therapy locally to the tumor site or to take advantage of existing immunological mediators, enhancing drug concentrations or therapeutic cell numbers while bypassing the blood-brain barrier to maximize efficacy and minimize systemic toxicity. Exciting local-therapy approaches have been proposed for these devastating tumors. In this review, we discuss the potential applications of bioreactors, neural stem cells, immunotherapies, biodegradable polymers, and convection-enhanced drug delivery in the treatment of malignant gliomas. These approaches are at different stages of readiness for application in clinical neurosurgery, and their eventual effects on the morbidity and mortality rates of gliomas among human patients are difficult to ascertain from successes in animal models. Nevertheless, we are entering an exciting era of "nanoneurosurgery," in which molecular therapies such as those discussed here may routinely complement existing surgical, radiological, and chemotherapeutic approaches to the treatment of neuro-oncological disease. The potential to deploy any of a number of eloquently devised molecular therapies may provide renewed hope for neurosurgeons treating malignant gliomas.

摘要

恶性胶质瘤是所有癌症中最难成功治疗的癌症之一,其特点不仅是侵袭性增殖和扩张,还在于肿瘤会无情地侵入远处的脑组织。尽管在通过手术、放疗和化疗联合治疗这些肿瘤方面已经取得了相当大的进展,但这些努力尚未达到治愈的效果。神经外科医生作为肿瘤学家,越来越多地将注意力转向分子层面的治疗方法。神经外科医生特别感兴趣的是能够将治疗药物局部递送至肿瘤部位,或者利用现有的免疫介质,在绕过血脑屏障的同时提高药物浓度或治疗性细胞数量,以最大限度地提高疗效并将全身毒性降至最低。针对这些毁灭性肿瘤,已经提出了令人兴奋的局部治疗方法。在本综述中,我们讨论了生物反应器、神经干细胞、免疫疗法、可生物降解聚合物和对流增强药物递送在恶性胶质瘤治疗中的潜在应用。这些方法在临床神经外科应用的准备阶段各不相同,从动物模型的成功中很难确定它们最终对人类患者胶质瘤发病率和死亡率的影响。然而,我们正在进入一个令人兴奋的“纳米神经外科”时代,其中本文讨论的分子疗法等可能会常规地补充现有的手术、放射和化学治疗方法,用于治疗神经肿瘤疾病。部署众多精心设计的分子疗法中的任何一种的潜力,可能会给治疗恶性胶质瘤的神经外科医生带来新的希望。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验